# p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer

> **NCT00525200** · PHASE3 · COMPLETED · sponsor: **Daniela Kandioler** · enrollment: 170 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** 5-Fluoruracil, Cisplatinum
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00525200
- **Lead sponsor:** Daniela Kandioler
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-12
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2012-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525200, "p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00525200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*